Abbott Q3 2022 Earnings Report
Key Takeaways
Abbott's Q3 2022 earnings showcased a mixed performance with a decrease in reported sales but an increase in organic sales. The company raised its full-year EPS guidance, driven by growth in U.S. Medical Devices and Established Pharmaceuticals, while navigating challenges in Nutrition and Diagnostics segments.
Worldwide sales reached $10.4 billion, a decrease of 4.7% on a reported basis but an increase of 1.3% organically.
GAAP diluted EPS was $0.81, with adjusted diluted EPS at $1.15.
Full-year 2022 EPS guidance was raised to $3.75 to $3.81 on a GAAP basis and $5.17 to $5.23 on an adjusted basis.
U.S. Medical Devices sales grew by 11.3%, driven by Electrophysiology, Structural Heart, and Diabetes Care.
Abbott
Abbott
Abbott Revenue by Segment
Abbott Revenue by Geographic Location
Forward Guidance
Abbott is raising its projected full-year 2022 diluted earnings per share under GAAP to $3.75 to $3.81. Excluding specified items, Abbott is raising its projected adjusted diluted earnings per share to $5.17 to $5.23 for the full-year 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income